X

BioCanCell Announces Appointment of Ms. Ruti Alon to Board of Directors

JERUSALEM, Aug. 14, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused…

admin

Notice of the Convening of an Extraordinary General Meeting of the Company’s Shareholders

BioCancell Ltd. (“the Company”) hereby announces the convening of an extraordinary general meeting ("the Meeting")…

admin

BioCancell Advances Intellectual Property Portfolio in the U.S.

Jerusalem, Israel, November 5, 2015, BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on…

admin

Biocancell advances phase III clinical program for bladder cancer

Jerusalem, Israel, October 1, 2015, BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on…

admin

Biocancell receives FDA fast track designation for BC-819 for treatment of bladder cancer patients

Jerusalem, Israel, September 10, 2015, BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on…

admin

Biocancell announces development of new diagnostic product BC-830

BioCancell Ltd. today announced that it has begun developing a new product, designated BC-830, for…

admin

BioCancell Files International Patent Request For New Drug Formulation

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) today announced that it had filed an international patent…

admin

BioCancell Receives Outline Approval for Two Phase III Bladder Cancer Trials

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) is pleased to announce that, following discussions held over…

admin

BioCancell Announces Results of Bladder Cancer Trial

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) announced today the results of a bladder cancer clinical…

admin

BioCancell Announces Final Phase IIb Bladder Cancer Trial Results

Jerusalem, Israel -- BioCancell Ltd. (TASE:BICL) today announced final results in its Phase IIb bladder cancer clinical…

admin